SCHEMBL1714985

SCHEMBL1714985

CN1C(=O)NC(=O)C12CCc1cc(Br)ccc1C2

nearest known ligand 0.42

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.42
AKR1B1 P15121 1/20 0.40
CALCRL Q16602 8/20 0.39
BACE1 P56817 5/20 0.38
TDP2 O95551 1/20 0.38
ASIC3 Q9UHC3 1/20 0.37
SRD5A1 P18405 1/20 0.36
CMA1 P23946 1/20 0.36
AHR P35869 1/20 0.36
CYP11B2 P19099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12921079 0.88 BRD4 (0.46) BRD4AKR1B1CALCRLCMA1AHR
SCHEMBL1921018 0.88 BRD4 (0.46) BRD4AKR1B1CALCRLCMA1AHR
SCHEMBL15935913 0.86 CALCRL (0.44) AKR1B1CALCRL
SCHEMBL4958656 0.84 CALCRL (0.41) CALCRL
SCHEMBL13015183 0.82 CALCRL (0.39) CALCRL
SCHEMBL12152864 0.81 CALCRL (0.43) CALCRL
SCHEMBL1715431 0.81 ALDH1A1 (0.44) CALCRLTDP2
SCHEMBL12622663 0.78 CALCRL (0.41) CALCRL
SCHEMBL12655216 0.78 CALCRL (0.41) CALCRL
SCHEMBL1814392 0.73 BACE1 (0.51) BRD4BACE1TDP2SRD5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011070283-A8 METHOD AND APPARATUS FOR COOLING AND/OR DEEP-FREEZING MATERIALS IMPLEMENTING THE INJECTION OF TWO CRYOGENIC LIQUIDS L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude (FR) 2012-05-10 WO disclosed
EP-1606264-B1 MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-05-02 EP disclosed
EP-1606264-B1 MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-05-02 EP disclosed
US-8071771-B2 Bicyclic spirohydantoin CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-12-06 US disclosed
US-8071770-B2 Spirohydantoin aryl CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-12-06 US disclosed
US-8071770-B2 Spirohydantoin aryl CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-12-06 US disclosed
US-8071770-B2 Spirohydantoin aryl CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-12-06 US disclosed
US-8071771-B2 Bicyclic spirohydantoin CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-12-06 US disclosed
EP-1613368-B1 CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2011-11-30 EP disclosed
EP-1613368-B1 CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2011-11-30 EP disclosed
US-7189722-B2 Aryl spirohydantoin CGRP receptor antagonists MERCK & CO., INC. (US) 2007-03-13 US disclosed
US-20060211712-A1 Bicyclic anilide spirohydantoin cgrp receptor antagonists MERCK SHARP & DOHME LLC 2006-09-21 US disclosed
US-20060189593-A1 Aryl spirohydantoin cgrp receptor antagonists MERCK SHARP & DOHME LLC 2006-08-24 US disclosed
US-20060189600-A1 Benodiazepine spirohydantoin cgrp receptor antagonists MERCK SHARP & DOHME LLC 2006-08-24 US disclosed
US-20060148779-A1 Monocyclic anilide spirohydantoin cgrp receptor antagonists MERCK SHARP & DOHME LLC 2006-07-06 US disclosed
WO-2006031676-A2 TRICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2006-03-23 WO disclosed
EP-1608627-A2 BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS Merck & Co. Inc. (US) 2005-12-28 EP disclosed
EP-1605936-A1 ARYL SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS Merck & Co. Inc. (US) 2005-12-21 EP disclosed
WO-2004082605-A2 BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK & CO. INC. (US) 2004-09-30 WO disclosed
WO-2004082678-A1 ARYL SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK & CO. INC. (US) 2004-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189600-A1 Benodiazepine spirohydantoin cgrp receptor antagonists BDKRB2, BDKRB1, CNR2 BRD4 278/4885AKR1B1 1117/4885CALCRL 7/4885
US-20060148779-A1 Monocyclic anilide spirohydantoin cgrp receptor antagonists CALCRL, CALCR, CCKAR BRD4 1394/4885AKR1B1 880/4885CALCRL 1/4885
US-20060211712-A1 Bicyclic anilide spirohydantoin cgrp receptor antagonists BDKRB2, CALCRL, CCKBR BRD4 1251/4885AKR1B1 674/4885CALCRL 2/4885
US-20060189593-A1 Aryl spirohydantoin cgrp receptor antagonists CALCRL, BDKRB2, MRGPRX1 BRD4 895/4885AKR1B1 826/4885CALCRL 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.